



CSE: IN
OTCQB: IMLFF

Suite 350– 409 Granville ST
Vancouver, BC, Canada V6C-1T2
Tel: 604.669.7207
Email: info@inmedpharma.com
www.inmedpharma.com

NEWS RELEASE

InMed Appoints Paul Brennan to the Board of Directors

Vancouver, BC – August 25, 2015 - InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (**CSE: IN; OTCQB: IMLFF**), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company’s Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.

Mr. Brennan is currently Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals). Previously he has held a number of senior management and consulting positions at biotech companies based in the U.S. and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for \$915 million. Mr. Brennan was also employed at AnorMED where he held a number of roles including Acting President during which time he was involved in the sale of AnorMED to Genzyme for \$580 million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.

"Paul’s extensive experience in the pharmaceutical and biotechnology industries, including senior leadership and board positions in several successful companies, will greatly complement and strengthen our Board," said Craig Schneider, President and CEO of InMed. We are delighted that he has accepted a position to the Board".

Mr. Brennan earned his B.Sc. in Life Sciences and his M.Sc. in Physiology from Queen’s University, in Kingston, Ontario.

InMed also wishes to announce it has accepted the resignation of Kevin Puil as a Director of the Company, effective today. The Board wishes to thank Mr. Puil for his efforts on behalf of the Company.

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.

For more information, visit www.inmedpharma.com.

Contact: InMed Pharmaceuticals Inc.

Craig Schneider
President and Chief Executive Officer
T: 604.669.7207
E: craig@inmedpharma.com

Investors:

Chris Bogart
SVP, Corporate Strategy and Investor Relations
T: 604.669.7207
E: chris@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about Mr. Brennan acting as a Director of the Company; and the fundamental value drivers of the company. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Mr. Brennan's continued ability to serve as a Director of the Company; continued demand for InMed's products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the possibility that Mr. Brennan will no longer be willing or able to serve on the Company's Board of Directors; InMed's proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value; and economic or market conditions may worsen.

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.